BNF 68 (British National Formulary) September 2014 - March 2015 pdf free download on one click from this blog easily from booksofmedicals.com in pdf format.
BNF is designed as a lift for quick reference and may not always contain all the information needed for prescribing and dispensing. Also, not much detail is given in areas such as obstetrics, malignancies, and anesthesia, as those who practice are expected to have expertise and access to professional literature. Detailed information on medication use in children should be consulted with the BNF for children. BNF should be interpreted in the light of expertise and supplemented according to the requirements of specialized publications and by reference to product literature. Information is also available from drug information services.
About BNF
BNF is a joint publication of the British Medical Association and the Royal Pharmaceutical Society. It is issued under the auspices of a Joint Formulation Committee composed of representatives of two professional bodies, the British Health Departments, the Agency for the Regulation of Medicines and Medical Products and the manufacturer of national guidelines. Dental Advisory Group oversees the preparation of dental and oral treatment management advice; the group includes representatives of the British Dental Association and representatives of the British Health Departments. The Prescribing Physicians Advisory Group provides advice on nurse-related content and includes representatives from different parts of the nursing community and the UK's health departments.
BNF aims to provide prescribers, pharmacists and other healthcare professionals with the latest information on drug use. The BNF contains important information on drug selection, prescribing, administration and administration. Medicines that are commonly prescribed in the UK are reimbursed and those that are considered less suitable for prescription are well known. Little or no information is included about drugs promoted for public purchase.
Drug information is taken from the manufacturers' product literature, medical and pharmaceutical literature, UK health departments, regulators and professional bodies. The advice is taken from the clinical literature and reflects, where possible, evaluations of evidence from a variety of sources. BNF also considers national guidelines and increased safety care to be authoritative. In addition, the newsroom received advice in all areas of treatment from specialist clinics; this ensures that BNF's recommendations are relevant to practice.
BNF is designed as a lift for quick reference and may not always contain all the information needed for prescribing and dispensing. Also, not much detail is given in areas such as obstetrics, malignancies and anesthesia, as those who practice are expected to have expertise and access to professional literature. Likewise, little or no information is included on orphan drugs. Detailed information on medication use in children should be consulted with the BNF for children. BNF should be interpreted in the light of expertise and supplemented according to the requirements of specialized publications and by reference to product literature. Information is also available from health information services, see Drug Information Services
(see content on the title page).
It is important to use the latest information on BNF for clinical decisions. The BNF printed edition is updated every year in March and September. Monthly updates are provided online through Medicines Complete and the NHS Evidence Portal. More important changes are in the Changes section; The changes are listed on the Internet as cumulative (from one printed edition to the next) and can be printed monthly to reflect major changes since the last print as an auxiliary book for those who use the printed version.
The BNF Publications website (www.bnf.org) provides additional information about healthcare professionals. Other BNF digital formats are also available - including mobile versions and integration with local formulas.
Guidance on prescribing
Medicines should only be prescribed when they are needed, and in any case the benefits of drug administration should be considered in relation to the associated risk. This is especially important during pregnancy, when the risk to the mother and fetus must be taken into account.
It is important to carefully discuss treatment options with the patient to ensure that the patient is satisfied with taking the prescription medication. In particular, the patient should be helped to distinguish the side effects of the prescribed drugs from the side effects of the disease. If the beneficial effects of the drug are likely to be delayed, the patient should be informed. For drug optimization instructions, see Drug Optimization on page 18.
Never Incidents Never Incidents are serious and preventable medical errors where preventive measures must be taken to stop their occurrence.
In the event of any drug or class-related incident, the BNF publication has information in the monographs in the Important Safety Information section. Prescribing Competence Framework The Royal Pharmaceutical Society has issued the Prescribing Competence Framework, which includes a common set of competencies that form the basis of prescribing, regardless of professional background. Opportunities are designed to help healthcare professionals become safe and effective prescribers in order to encourage patients to achieve the best results from their medications.
Biological drugs
Biological drugs are drugs produced or obtained from a biological source by biotechnological processes, such as recombinant DNA technology. The size and complexity of biological drugs, as well as the method of their production, can result in a certain degree of natural renewal of the molecules of the same active substance, especially for different groups of drugs. This distinction is kept within strictly acceptable limits. Examples of biological drugs include insulin and monoclonal antibodies. g Biological medicines must be prescribed and the prescribed label must be provided to prevent unintentional transmission. Automatic label exchange at the point of delivery is not suitable for biological medicines. h
Biosimal drugs
A biosilar drug is a biological drug that is very similar and clinically equivalent (in terms of quality, safety and efficacy) to an existing biological drug already approved by the European Union (known as the reference biological drug of origin). The active substance of a biosimal drug is similar but not identical to the biological origin of the drug. Once a biological drug patent expires, the biosimal drug can be authorized by the European Medicines Agency (EMA). A biosilar drug is not the same as a generic that has a simpler molecular structure similar to the original drug.
Therapeutic equivalence g Biosimal drugs should be considered therapeutically equivalent to the original biological drug within their permitted designations. h Biosimal drugs are generally licensed for all indications of biological drug development, but are subject to evidence submitted to the EMA for approval and must be scientifically substantiated by proven or extrapolated agreement. Prescribing and administering The choice of prescribing a biosimal drug or a drug of biological origin is up to the physician in consultation with the patient. g Biological drugs (including biosimal drugs) must be prescribed and labeled to prevent prescription. Automatic label exchange at the point of delivery is not suitable for biological medicines.
Shortened to subtitles
In general, drug and product names should be written in full. Unofficial abbreviations should not be used as they may be misinterpreted.
Non-proprietary titles
If unprotected ("generic") names are provided, they should be used in prescribing. This allows any suitable product to be delivered, thus saving patient delays and sometimes healthcare costs. The only exception is when there is a difference in clinical effect between each version of the product, which is important so that the patient always receives the same brand; in such cases, the brand or manufacturer name must be given. Non-proprietary names should not often be devised for prescribing, as this can lead to confusion, especially in the case of compound and controlled release products.
Names used as monograph names may be used freely in the United Kingdom, but may be banned in other countries.
Many of the unprotected titles used in this book are the titles of the monographs of the European Pharmacopoeia, the British Pharmacopoeia or the British Pharmaceutical Code 1973. In such cases, the products must comply with the standard (if any) of the relevant publication, if necessary. . under the Medicinal Products for Human Use Regulation 2012.
This site complies with DMCA digital copyright laws. Please note that we do not own the rights to this book / software. We do not host copyrighted content on our servers, it is a catalog of links already found on the Internet.
Booksofmedical.com does not contain any server-hosted material on this site, only links to books taken from other websites are published here, and these links are not linked to the book server.
In addition, Medicalstudyzone.com does not store any books, guides, software, or images. No illegal copies are made or there is no infringement or copyright infringement © and/or copyrights because all material is free on the Internet. See our DMCA policy. If you believe we have infringed your copyright, please contact us directly. We share them with our audience for educational purposes ONLY and strongly encourage our visitors to purchase original software/books and licenses. {alertInfo}
If the copyright holder wants us to remove this software / book, please contact us. You can send an email to DMCA@booksofmedical.com for any DMCA / removal requests. {alertSuccess}